Voruciclib Polymorphs With X-Ray Fingerprint Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing chemical compounds, including drugs, exhibit variations in polymorphic forms that affect their quality and performance, such as bioavailability and stability, which are not adequately addressed by current physicochemical measurement techniques.
Innovation Solution
The development of novel polymorphs of CDK inhibitor voruciclib, characterized by specific X-ray powder diffraction patterns, including forms such as voruciclib malonate, dibenzoyl-tartrate, phosphate, oxalate, and napadisylate, which provide distinct crystalline structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polymorphic forms of voruciclib are used, then stability and bioavailability are improved, but identification and characterization become more difficult
Solution Approach 1:
The patent uses X-ray diffraction patterns as a 'fingerprint' characterization method to distinguish between different polymorphic forms of voruciclib. Each polymorph exhibits unique diffraction peak patterns at specific 2θ angles, enabling reliable identification and differentiation of crystal forms without requiring complex additional measurements.
Solution Approach 2:
The patent replaces complex physicochemical measurement techniques with X-ray powder diffraction analysis for polymorph identification. This substitution provides a simpler, more direct method for characterizing crystal forms based on their distinctive diffraction patterns rather than relying on multiple indirect measurements.
2Reliability
If multiple polymorphic forms are developed, then therapeutic effectiveness is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs counterion exchange as a controlled parameter change to convert between different polymorphic forms of voruciclib. By systematically varying the counterion (e.g., from chloride to malonate to dibenzoyl-tartrate), the patent achieves predictable transitions between crystal forms with different therapeutic properties, simplifying the manufacturing process compared to developing multiple distinct compounds.
Solution Approach 2:
The patent creates a universal voruciclib platform where a single active molecule can exist in multiple polymorphic forms, each serving different therapeutic indications. This multi-functionality allows one compound to address various diseases (blood cancers, solid tumors, hyperproliferative disorders) through polymorph selection, reducing the need for multiple separate drug development programs.
3Reliability
If polymorph characterization is enhanced, then drug performance is improved, but measurement precision requirements increase
Solution Approach 1:
The patent utilizes the distinctive X-ray diffraction patterns of each polymorph as unique identifiers. The diffraction peaks appear at specific 2θ angles (e.g., Form 1 shows peaks at 7.30°±0.2°, 13.58°±0.2°, 14.06°±0.2°), providing clear, unambiguous characterization that does not require ultra-high measurement precision beyond the stated tolerances.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These polymorphs enhance the stability and bioavailability of voruciclib, enabling effective treatment of various diseases, including blood cancers and hyperproliferative disorders, by providing therapeutically effective compositions.
Implementation Method 1
various physicochemical measurements and techniques may be used to explore and identify polymorphs, including melting point determination, infra red spectroscopy (IR), X-ray diffraction
Implementation Method 2
characterized by an X-ray powder diffraction pattern including one or more peaks selected from 7.30°±0.2°, 13.58°±0.2°, 14.06°±0.2°, 15.18°±0.2°, 15.66°±0.2°, 17.50°±0.2°, 18.94°±0.2°, 19.54°±0.2°, 22.22°±0.2°, 23.38°±0.2°, 24.10°±0.2°, 24.98°±0.2°, 25.94°±0.2°, 27.26°±0.2°, 28.50°±0.2°, and 32.82°±0.2° 2θ
Implementation Method 3
Certain chemical compounds, including various drugs, may exist in polymorphic forms. Polymorphic forms generally refer to different crystalline forms with different physical properties
Data Source
AI summary
The disclosure relates to crystalline solid forms of voruciclib, including voruciclib free base and various voruciclib salts, pharmaceutical compositions containing voruciclib crystalline solid forms, and methods for treating conditions or disorders by administering pharmaceutical compositions including voruciclib crystalline solid forms.